Postmenopausal craniofacial hyperhidrosis

Eustace, Karen; Wilson, N. J. E.

doi:10.1111/ced.13310

Cited by 7 publications

(12 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, there is a lack of diagnostic consistency, which may complicate the clinician's decision. 17,26 This study revealed more similarities between hyperhidrosis and VMS than expected. Two of the patients had vasomotor symptoms (sweating, including night sweating and flushes) but also heredity for hyperhidrosis and typical primary hyperhidrosis as teenagers.…”

Section: Discussionsupporting

confidence: 52%

“…More education is needed to make it easier for physicians to distinguish between VMS and hyperhidrosis. However, there is a lack of diagnostic consistency, which may complicate the clinician's decision …”

Section: Discussionmentioning

confidence: 99%

“…In this article, descriptive data is presented concerning a subgroup of eight postmenopausal patients participating in a clinical trial investigating the clinical effect and safety of Btx type B in craniofacial hyperhidrosis. This subtype of craniofacial hyperhidrosis is often underrecognized and challenging to treat …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Postmenopausal craniofacial hyperhidrosis treated with botulinum toxin type B

Cabreus¹,

Swartling

Rystedt³

2019

The Journal of Dermatology

View full text Add to dashboard Cite

Hyperhidrosis can seriously impair patients’ quality of life. Medical history, including heredity and hyperhidrosis during youth, as well as current age and time elapsed since menopause, is important to consider when distinguishing between postmenopausal hyperhidrosis and vasomotor symptoms to enable adequate treatment. This report concerns a subgroup of eight postmenopausal patients participating in a randomized controlled trial regarding botulinum toxin (Btx) type B treatment in craniofacial hyperhidrosis. Even though the sample size is small and the enrolment is not yet completed, the promising data collected hitherto are interesting to present in advance because this subtype of craniofacial hyperhidrosis is often underrecognized and challenging to treat. Patients were randomized to receive Btx type B or placebo. Measurements were performed before treatment and 3 ± 1 weeks after. The Dermatology Life Quality Index (DLQI) score was improved for all patients after Btx type B treatment (n = 3) with a median decrease of 9 points (90% median improvement). The placebo group (n = 5) had a median increase of 2 points (–18% median decline). When the same group (n = 5) received Btx type B (open) the DLQI score decreased with a median of 7 points compared with baseline (91% median improvement). Treatment‐related adverse events were temporary and did not prevent improvement of life quality. Furthermore, background data evaluation uncovered interesting findings regarding vasomotor symptoms in relation to postmenopausal hyperhidrosis. In conclusion, the results indicated that Btx type B seems to be a safe and effective treatment in postmenopausal craniofacial hyperhidrosis. Further research is encouraged.

show abstract

Section: Discussionsupporting

confidence: 52%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Postmenopausal craniofacial hyperhidrosis treated with botulinum toxin type B

Cabreus¹,

Swartling

Rystedt³

2019

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…La hiperhidrosis del cuero cabelludo (HHCC) es un problema relativamente común y con gran impacto negativo en la calidad de vida de los pacientes 1 . Sin embargo, existen pocos estudios científicos centrados en esta ubicación específica y, de forma general, se limitan a hablar de hiperhidrosis craneofacial sin distinguir entre cara y/o cuero cabelludo [1][2][3][4][5][6] . Además, para esta localización especial, existen pocas alternativas terapéuticas disponibles, siendo los anticolinérgicos orales habitualmente considerados el tratamiento de elección y, concretamente, la oxibutinina oral (OxO) el más usado 7 , si bien, no existen estudios centrados en valorar su uso específicamente en la HHCC.…”

Section: Introductionunclassified

Hiperhidrosis del cuero cabelludo: particularidades clínicas y de respuesta al tratamiento con oxibutinina oral

González¹,

García‐Souto²

2022

Más Dermatol

View full text Add to dashboard Cite

“…Craniofacial HH is a relatively infrequent subtype, although it is probably underdiagnosed and its classification in scientific articles is often nonspecific and unclear. In general, the term craniofacial HH refers to HH that affects the face and/or scalp, although the vast majority of studies refer to it without distinguishing the areas affected, that is, one or the other or both 12 …”

Section: Introductionmentioning

confidence: 99%

Craniofacial hyperhidrosis: Clinical characteristics and response to treatment in a cohort of 97 patients treated with oral oxybutynin

García‐Souto

Boz

Colmenero-Sendra

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

The term craniofacial hyperhidrosis (HH) refers to HH that affects the face and/or scalp. Few studies have focused on this specific location, and even fewer distinguish between the two areas. Our study aims are to describe the clinical characteristics of patients with craniofacial HH, specifying whether the condition affects the scalp, face or both, and to compare these cases with those recorded at other locations. As secondary objectives, we determine the effectiveness and adverse effects of oral oxybutynin (OOx), and assess patients' adherence to treatment. This prospective observational study was carried out with respect to the period 2007‐2019. All patients diagnosed with HH of the scalp and/or face and who were treated with OOx at our HH unit were included in the study group. Of 292 patients treated with OOx, 97 (33.2%) had craniofacial HH. Of these, 4 (4.1%) presented HH exclusively on the scalp, 56 (57.7%) exclusively on the face and 37 (38.1%) in both locations. The patients in the latter category (compared with those with exclusively facial HH) were significantly older than the others, had a later onset of HH, a greater frequency of secondary HH, less simultaneous involvement of the classical areas of primary focal HH (the palms, soles, and armpits) and greater generalized HH and of the trunk. No significant differences were observed between the three locations (face, scalp, or both) regarding the efficacy and side effects of OOx. The patients with exclusively facial HH presented greater adherence to treatment.

show abstract

Postmenopausal craniofacial hyperhidrosis

Cited by 7 publications

References 5 publications

Postmenopausal craniofacial hyperhidrosis treated with botulinum toxin type B

Postmenopausal craniofacial hyperhidrosis treated with botulinum toxin type B

Hiperhidrosis del cuero cabelludo: particularidades clínicas y de respuesta al tratamiento con oxibutinina oral

Craniofacial hyperhidrosis: Clinical characteristics and response to treatment in a cohort of 97 patients treated with oral oxybutynin

Contact Info

Product

Resources

About